Somatic mutation testing should be more widespread among patients with endometrial cancer, as a significant percentage of them are found to harbor BRCA1/2
mutations and could benefit from PARP inhibitors, explained Julia Fehniger, MD.
In a study presented during the 2020 SGO Winter Meeting, investigators evaluated 89 women who were treated for advanced or recurrent endometrial cancer at NYU Langone Health’s Perlmutter Cancer Center from January 2013 to July 2019. Genomic alterations, including microsatellite instability (MSI) and tumor mutational burden (TMB), were recorded and compiled with descriptive statistics of patients both with and without somatic BRCA1/2
mutations. Thirteen (15%; 95% CI, 8-24) patients had BRCA1/2
“Although you may think that patients with endometrial cancer don't necessarily have a BRCA
-associated cancer, their tumors can harbor mutations in BRCA1/2
,” said Fehniger. “We identified 15% of patients [with these mutations], suggesting that there's not an insignificant percentage of patients who may be able to benefit from PARP inhibitors. It is important to further characterize tumors with clinical trials in the future.”
... to read the full story